We are leading a new wave of therapeutic development. Our pipeline encompasses antenatal protein replacement and highly differentiated topical antisense technology to address patients with rare diseases.

integrated product platforms

Dermelix is determined to make a meaningful impact on the lives of patients suffering with rare genetic skin diseases by developing and bringing to market a range of innovative therapeutics.